4-氯-2-苯基甲氧基吡啶 | 1006052-55-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4-氯-2-苯基甲氧基吡啶
• 中文别名: 2-(苄氧基)-4-氯吡啶
• 英文名称: 4-chloro-2-benzyloxypyridine
• 英文别名: 2-benzyloxy-4-chloro-pyridine；2-(Benzyloxy)-4-chloropyridine；4-chloro-2-phenylmethoxypyridine
• CAS: 1006052-55-6
• 化学式: C₁₂H₁₀ClNO
• 分子量: 219.671
• InChiKey: YVYOMLRBHNXGEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-氯-2-苯基甲氧基吡啶 在 盐酸 、 tris-(dibenzylideneacetone)dipalladium(0) 、 palladium 10% on activated carbon 、 水 、 氢气 、 sodium hydride 、 1-羟基苯并三唑 、 lithium hydroxide 、 sodium t-butanolate 、 2-二环己膦基-2'-(N,N-二甲胺)-联苯 作用下， 以 甲醇 、 乙醇 、 正己烷 、 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 30.58h， 生成 R-1-[2-(4-diethylamino-2-oxo-2H-pyridin-1-yl)acetamido]-3-methylbutylboronic acid
  参考文献：
  名称：

  Development of peptidomimetic boronates as proteasome inhibitors

  摘要：

  Proteasome inhibition has emerged over the past decade as an effective therapeutic approach for the treatment of hematologic malignancies. It is a multicatalytic complex, whose proteolytic activity relies in three types of subunits: chymotrypsin-like (beta 5), trypsin-like (beta 2) and caspase-like (beta 1). Most important for the development of effective antitumor agents is the inhibition of the beta 5 subunits. In this context, the dipeptide boronate bortezomib (Velcade (R)) represents the first proteasome inhibitor approved by the FDA and the lead compound in drug discovery. This paper describes the synthesis and biological evaluation of a series of conformationally constrained pseudopeptide boronates (1-3) structurally related to bortezomib. The synthesized compounds showed a promising inhibitory profile by blocking primarily the chymotrypsin-like activity of the proteasome with K-i values in submicromolar/micromolar range. These compounds also resulted quite selective since no significant inhibition was recorded in the test against bovine pancreatic alpha-chymotrypsin. The obtained results were rationalized by means of docking experiments based on a model of the crystal structure of bortezomib bound to the yeast 20S proteasome providing essential insights for further optimization of this class of inhibitors. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.032
• 作为产物：
  描述：

  2,4-二氯吡啶 、 苯甲醇 在 potassium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 以87%的产率得到4-氯-2-苯基甲氧基吡啶
  参考文献：
  名称：

  Development of peptidomimetic boronates as proteasome inhibitors

  摘要：

  Proteasome inhibition has emerged over the past decade as an effective therapeutic approach for the treatment of hematologic malignancies. It is a multicatalytic complex, whose proteolytic activity relies in three types of subunits: chymotrypsin-like (beta 5), trypsin-like (beta 2) and caspase-like (beta 1). Most important for the development of effective antitumor agents is the inhibition of the beta 5 subunits. In this context, the dipeptide boronate bortezomib (Velcade (R)) represents the first proteasome inhibitor approved by the FDA and the lead compound in drug discovery. This paper describes the synthesis and biological evaluation of a series of conformationally constrained pseudopeptide boronates (1-3) structurally related to bortezomib. The synthesized compounds showed a promising inhibitory profile by blocking primarily the chymotrypsin-like activity of the proteasome with K-i values in submicromolar/micromolar range. These compounds also resulted quite selective since no significant inhibition was recorded in the test against bovine pancreatic alpha-chymotrypsin. The obtained results were rationalized by means of docking experiments based on a model of the crystal structure of bortezomib bound to the yeast 20S proteasome providing essential insights for further optimization of this class of inhibitors. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.03.032

文献信息

• Substituted Benzamide Compounds
  申请人：Reich Melanie

  公开号：US20120071461A1

  公开（公告）日：2012-03-22

  Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

  对应于式(I)的取代苯甲酰胺化合物，其中R5、R6、R7、R8、a、b、c、d、t、D和X具有定义的含义，其制备方法，包括这些化合物的药物组合物，以及使用这些化合物治疗疼痛和其他至少部分通过激肽酶1受体介导的疾病的方法。
• Deuterodechlorination of Aryl/Heteroaryl Chlorides Catalyzed by a Palladium/Unsymmetrical NHC System
  作者：Masami Kuriyama、Norihisa Hamaguchi、Gemba Yano、Kotaro Tsukuda、Kanako Sato、Osamu Onomura

  DOI：10.1021/acs.joc.6b01609

  日期：2016.10.7

  The catalytic deuterodechlorination of aryl/heteroaryl chlorides was developed with a palladium/unsymmetrical NHC system, and the precisely controlled introduction of deuterium into a variety of aryl/heteroaryl compounds was achieved with a high level of efficiency, selectivity, and deuteration degree. This method was also successfully applied to the transformation of bioactive agents even in a gram-scale

  利用钯/不对称NHC体系开发了对芳基/杂芳基氯化物的催化氘代脱氯反应，并以高水平的效率，选择性和氘化度实现了将氘精确控制引入各种芳基/杂芳基化合物中的方法。即使在克级合成中，该方法也成功地应用于生物活性剂的转化。Pd-NHC配合物的晶体结构分析导致观察到Pd-芳烃相互作用。
• [DE] SUBSTITUIERTE BENZAMID-VERBINDUNGEN<br/>[EN] SUBSTITUTED BENZAMIDE COMPOUNDS<br/>[FR] COMPOSÉS DE BENZAMIDE SUBSTITUÉS
  申请人：GRUENENTHAL GMBH

  公开号：WO2012038081A1

  公开（公告）日：2012-03-29

  Die vorliegende Erfindung betrifft substituierte Benzamid-Verbindungen, Verfahren zu deren Herstellung, Arzneimittel enthaltend diese Verbindungen und die Verwendung von substituierten Benzamid-Verbindungen zur Herstellung von Arzneimitteln. Die Verbindungen sind nützlich als B1R -Modulatoren zur Behandlung von z.B. Schmerz.

  本发明涉及取代苯甲酰胺化合物，其制备方法，含有这些化合物的药物以及使用取代苯甲酰胺化合物制备药物。这些化合物在治疗疼痛等方面是有用的B1R调节剂。
• Bradykinin 1 receptor modulating compounds
  申请人：Reich Melanie

  公开号：US08680159B2

  公开（公告）日：2014-03-25

  Substituted benzamide compounds corresponding to formula (I) in which R5, R6, R7, R8, a, b, c, d, t, D and X have defined meanings, a process for their preparation, pharmaceutical compositions comprising such compounds, and a method of using such compounds to treat pain and other conditions mediated at least in part via the bradykinin 1 receptor.

  本发明涉及一种对应于式（I）的取代苯甲酰胺化合物，其中R5、R6、R7、R8、a、b、c、d、t、D和X具有定义的含义，以及其制备方法、包含这些化合物的制药组合物，以及使用这些化合物治疗通过部分介导于Bradykinin 1受体的疼痛和其他病症的方法。
• SUBSTITUIERTE BENZAMID-VERBINDUNGEN
  申请人：Grünenthal GmbH

  公开号：EP2619178A1

  公开（公告）日：2013-07-31